# CEP-701 (Lestaurtinib) in Myelofibrosis

> **NCT00668421** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ronald Hoffman** · enrollment: 60 (actual)

## Conditions studied

- Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera

## Interventions

- **DRUG:** CEP-701 (Lestaurtinib)

## Key facts

- **NCT ID:** NCT00668421
- **Lead sponsor:** Ronald Hoffman
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2013-09
- **Final completion:** 2015-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668421, "CEP-701 (Lestaurtinib) in Myelofibrosis". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00668421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*